NCT06959537 2026-05-20A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)M.D. Anderson Cancer CenterPhase 1 Recruiting24 enrolled